Biologic agents in the treatment of inflammatory rheumatic diseases

In 1997, knowledge about the treatment of autoimmune rheumatic diseases increased further. The most promising data to date came from studies using tumor necrosis factor-alpha blocking agents, such as monoclonal antibodies or soluble receptor constructs. Clinical trials with these compounds have now advanced to phase III; however, long-term safety data are not yet available. In addition, new developments with regard to T-helper cell-directed treatment principles, anti-inflammatory cytokines, and adhesion molecules are discussed.